Related Experiment Videos
Tumor necrosis factor inhibitors for rheumatoid arthritis
1Department of Medicine, University of Alabama at Birmingham, USA.
Abstract:
Tumor necrosis factor antagonists such as infliximab and etanercept represent a new and powerful approach to managing RA. In studies published to date, TNF antagonists appear to be safe and effective agents for short-term therapeutic use in RA. Defining when in the course of RA to use TNF antagonists and determining the effectiveness of combinations of these biologic agents with DMARDs or other cytokine antagonists are areas of current and future studies. Other cytokine antagonists that may be promising subjects for further study are IL-1 antagonists. Like TNF, IL-1 is a member of the inflammatory cascade, but may play a different role in the development of inflammatory arthritis. In animal models, inhibition of TNF suppressed the inflammatory response while IL-1 antagonism prevented joint destruction (2). These results imply that combination therapy providing inhibition of both IL-1 and TNF might be an effective treatment in humans with RA, but clinical trials in humans have not yet been performed. Studies are underway in people with early RA to determine if the new TNF inhibitors are more effective or safer than currently available therapies, such as methotrexate. Other agents that inhibit TNF activity are also being tested at this time in people with RA.
Insights
Tumor necrosis factor (TNF) antagonists show promise for rheumatoid arthritis (RA) management. Further research is needed to define optimal use and combination therapies for long-term effectiveness and safety.
Area of Science:
- Immunology
- Rheumatology
- Pharmacology
Background:
- Rheumatoid arthritis (RA) is a chronic inflammatory condition.
- Tumor necrosis factor (TNF) antagonists like infliximab and etanercept are emerging therapies for RA.
- Current understanding suggests TNF antagonists are safe and effective for short-term RA treatment.
Purpose of the Study:
- To explore the role of TNF antagonists in managing RA.
- To investigate the potential of combination therapies involving cytokine antagonists.
- To assess the efficacy and safety of new TNF inhibitors in early RA.
Main Methods:
- Review of published studies on TNF antagonists in RA.
- Exploration of IL-1 antagonists as potential therapeutic agents.
- Ongoing clinical trials evaluating TNF inhibitors in early RA patients.
Main Results:
- TNF antagonists demonstrate short-term safety and efficacy in RA.
- Animal models suggest IL-1 antagonism may prevent joint destruction.
- Combination therapy with TNF and IL-1 inhibition is hypothesized but not yet clinically tested.
Conclusions:
- TNF antagonists represent a powerful new approach for RA management.
- Further studies are required to determine optimal timing and combination strategies for TNF antagonists.
- IL-1 antagonists warrant further investigation for their role in inflammatory arthritis and potential combination therapy.